Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need For Specialty Handling

Somerset, N.J. – Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today announced several expanded capabilities within its European Clinical Supply Services network. The expansions have been implemented in response to increased customer demand for specialty clinical packaging, where the proportion of highly-potent or temperature-sensitive investigational medical products continues to increase.

At its Schorndorf, Germany facility, Catalent tripled its frozen storage (-18°C) capacity and has added a second automated Inova® packaging line for pre-filled syringes, with capabilities including plunger-rod insertion, application of single panel labels, finger flanges, and safety device mounting. At its controlled substances facility in Deeside, UK, the company has expanded its clinical storage capacity with the addition of a third vault, bringing the combined controlled substance storage capacity to over 14,000 cubic feet. The Bathgate, UK facility's cold storage capabilities have been updated to include a cryogenic storage service, suitable for stem cells, regenerative therapies and other clinical materials.

And finally, at Catalent's primary packaging facility, in Bolton, UK, the company has installed two new energy-efficient chiller units that increase output capacity by more than 10%.

"As with our recent investments in our US capabilities, we are committed to offering comprehensive clinical supply solutions throughout our European network,"commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent's Clinical Supply Services business. "A key part of that commitment is ensuring that our facilities are well aligned with the current, emerging and future needs of our customers, as evidenced by our recent investments in Europe and the harmonization of key systems across all Catalent sites."

The 60,000 sq. ft. Schorndorf facility offers primary and secondary packaging for oral dose solids and pre-filled syringes; cold, frozen and controlled drug clinical storage; and EU-GMP audit, importation, release and consulting services. The 125,000 sq. ft. Deeside facility provides comprehensive primary and secondary packaging services, with extensive capabilities in the cold storage of temperature-sensitive and controlled drug substances handling. The 141,000 sq. ft. Bathgate facility provides primary and secondary packaging services and returns and destruction management. The 61,000 sq. ft. Bolton facility offers state-of-the-art clinical supply services and is capable of supporting a range of primary and secondary packaging projects, from early stage clinical studies to specialty commercial packaging needs, including cold storage or highly-potent drugs handling. All four sites provide end-to-end clinical supply solutions that also include clinical supply management and comparator sourcing.

Inova® is a registered trademark of Optima Packaging Group GmbH. 

Media Contacts: 
Chris Halling
+44 (0)7580 041073
[email protected]

Richard Kerns
+44 (0) 161 728 5880
[email protected] 


Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as "believe," "expect," "anticipate", "intend", "estimate", "plan", "project", "foresee", "likely", "may", "will", "would" or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.'s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption "Risk Factors" in its Form 10-K release for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.